Irinotecan Liposomes as Maintenance for Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new form of the chemotherapy drug irinotecan (inside tiny fat particles) as a maintenance treatment for people with metastatic colorectal cancer that has responded well to initial chemotherapy. It aims to keep the cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have metastatic colorectal cancer that is pMMR or MSS.
- Your tumor responded (shrank, disappeared, or stayed stable) after 12-16 weeks of your first chemotherapy.
- You are in good enough health to do daily activities (ECOG 0-1).
- You do not have brain metastases, active infections, or serious organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.